Lykos Therapeutics

Lykos Therapeutics, formerly MAPS Public Benefit Corporation, is a company dedicated to transforming mental healthcare by developing and commercializing novel psychedelic therapies. The company's primary focus is on MDMA-assisted therapy for PTSD, having completed two Phase 3 trials and submitted a New Drug Application (NDA) to the FDA for approval. Lykos aims to integrate psychedelic-assisted therapies into the healthcare system, creating more tools available for mental health treatment and destigmatizing conversations around mental health.

Lykos is committed to operating as a public benefit corporation, prioritizing impact on people, communities, and society alongside financial success. They are ambitious in their goals, bold in their actions, and committed to prioritizing access to affordable, effective treatments for those in need. The company embraces transparency, diversity, equity, and inclusion in all aspects of its operations, and is dedicated to advancing the entire psychedelic ecosystem through open science, research innovation, and a focus on quality and safety.

Lykos Therapeutics does not explicitly mention job flexibility in their website content or any of the provided job postings. Therefore, it is not possible to determine the level of flexibility offered at the company.

Lykos Therapeutics is a public benefit corporation dedicated to transforming mental healthcare by developing and commercializing investigational psychedelics to bring better treatments to those living with mental health conditions. They are committed to challenging the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions, with an initial focus on post-traumatic stress disorder (PTSD).

Lykos Therapeutics promotes a culture of innovation, integrity, openness, and care. They are ambitious in their goals and bold in their actions, prioritizing resources to advance their mission of transforming mental healthcare. The company values transparency, inclusivity, and ethical business practices, emphasizing compassion and respect for all stakeholders, including patients, employees, and the wider psychedelic ecosystem.

Lykos Therapeutics is committed to diversity, equity and inclusion, striving to be a company that welcomes and empowers underrepresented voices. Their values of Openness and Care are reflected in their efforts to create an inclusive environment, ensuring transparency and treating everyone with respect. They actively measure their performance in this area and are transparent in their reporting.